Displaying 101–125 of 10943 results for
Quality & Compliance: “Flawless” may not exist on the plant floor, but reviewing your quality process can save money and lives.
Amgen and Belgian partners at UCB announced that the EMA has adopted a negative opinion on Evenity, for the treatment of osteoporosis in men and in postmenopausal women at increased risk of fracture.
Automation & Control: Single-use technologies offer multiple benefits for those who can overcome instrumentation challenges.
Biosimilar commercialization challenges, real-world tips for updating aging facilities and a deep dive into interchangeability guidance.
How those in the outsourcing sector can be more prepared to meet shifting customer demands as the industry continues to evolve.
Critics have taken aim at Novartis for its ties to a company that bought APIs in Syria that could have been used to make chemical weapons.
The FDA has given Dupixent the go-ahead as a treatment for nasal polyps.
A Q&A about the FDA DSCSA Pilot Program Pilot
The newly combined company will be led by Abbvie chairman and CEO Richard Gonzalez.
The warning letter is the result of an inspection of the company’s Somerset, New Jersey-based plant in July and August 2018.
CPhI N. America's keynote speaker explains what bipartisan bickering means for pharma
Eliminating siloed systems in favor of streamlined applications allows for greater agility and stronger collaboration, enabling pharma to meet the new quality management demands
Shared pursuits might lead to bigger rewards
The FDA has approved a new medication created to treat hypoactive sexual desire disorder in premenopausal women.
Bristol-Myers Squibb’s efforts to increase treatment indications for its immunotherapy blockbuster, Opdivo, have hit a bump in the road.
Sun Pharmaceutical said it has received four observations from the U.S. FDA for its Halol facility in Gujarat.
Just days after receiving approval in Japan, Daiichi Sankyo said the U.S. FDA will not approve its drug, quizartinib, as a treatment for adults with a type of blood cancer.
Why the industry is forming bonds with CBD
As GlaxoSmithKline readies a spin-off of its consumer healthcare business, the company is looking to shed certain parts of its portfolio.
Merck and Co. is scouting for a replacement for its CEO, Kenneth Frazier.
Online pharmacy Valisure reported that it found a new carcinogenic impurity in some lots of blood pressure medicine valsartan, but the amount is still well below levels the FDA deemed potentially harmful.
Japan is the first country to approve the drug, which targets patients with NTRK fusion-positive solid tumors, across 10 different tumor types.